Predictors of immunity after hepatitis a vaccination in HIV-infected persons

Journal of Viral Hepatitis

Volumn 14, Issue 3, 2007, Pages 189-193

  Overton, E T ^a   Nurutdinova, D ^a   Sungkanuparph, S ^a   Seyfried, W ^a   Groger, R K ^a   Powderly, W G ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Hepatitis A virus; Human immunodeficiency virus; Vaccination

Indexed keywords

HEPATITIS A VACCINE; VIRUS RNA;

ADULT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HEPATITIS A; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; IMMUNOCOMPETENCE; LOGISTIC REGRESSION ANALYSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; VACCINATION; VIREMIA;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HIV; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; RNA, VIRAL; SEX FACTORS; VIRAL LOAD; VIRUS REPLICATION;

EID: 33846967799     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2006.00822.x     Document Type: Article

References (19)

1. ACIP. Prevention of hepatitis A through active or passive immunization: recommendations of the Adivsory Committee on Immunization Practices. MMWR Recomm Rep 1999; 48: 1-37.
2. Wallace MR, Hill HE, Tasker SA, Miller LK. Hepatitis A in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 27(3): 651-653.
3. Fonquernie L, Meynard JL, Charrois A, Delamare C, Meyohas MC, Frottier J. Occurrence of acute hepatitis A in patients infected with human immunodeficiency virus. Clin Infect Dis 2001; 32(2): 297-299.
4. Vento S, Garofano T, Renzini C et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338(5): 286-290.
5. Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, Andre FE. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995; 171 (Suppl. 1): S44-S49.
6. Neilsen GA, Bodsworth NJ, Watts N. Response to hepatitis A vaccination in human immunodeficiency virus-infected and uninfected homosexual men. J Infect Dis 1997; 176: 1064-1067.
7. Santagostino E, Gringeri A, Rocino A, Zanetti A, deBiasi R, Mannucci PM. Patterns of immunogenicity of an inactivated hepatitis A vaccine in anti-HIV positive and negative hemophilic patients. Thromb Haemost 1994; 72: 508-510.
8. Tilzey AJ, Palmer SJ, Harrington C, O'Doherty MJ. Hepatitis A vaccine responses in HIV-positive persons with haemophilia. Vaccine 1996; 14: 1039-1041.
9. Hess G, Clemens R, Bienzle U, Schonfeld C, Schunck B, Bock HL. Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men. J Med Virol 1995; 46: 40-42.
10. Kemper CA, Haubrich R, Frank I et al. Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. J Infect Dis 2003; 187: 1327-1331.
11. Wallace MR, Brandt CJ, Earhart KC et al. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis 2004; 39: 1207-1213.
12. Tedaldi EM, Baker RK, Moorman AC et al. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis 2004; 38: 1478-1484.
13. Rainer Weber R, Friis-Møller N, Sabin C, et al. HIV and Non-HIV-related Deaths and Their Relationship to Immunodeficiency: The D:A:D Study. Proceedings of the Twelfth Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 22-25 February 2005, Abstract no. 595.
14. Weissman S, Feucht C, Moore BA. Response to hepatitis A vaccine in HIV-positive patients. J Viral Hepat 2005; 13(2): 81-86.
15. Overton ET, Sungkanuparph S, Powderly WG, Seyfried W, Groger RK, Aberg JA. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005; 41(7): 1045-1048.
16. Valdez H, Smith KY, Landay A et al. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. AIDS 2000; 14: 11-21.
17. Kroon FP, Rimmelzwaan GF, Roos MT et al. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS 1998; 12: F217-F223.
18. Fuller JD, Craven DE, Steger KA, Cox N, Heeren TC, Chernoff D. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin Infect Dis 1999; 28: 541-547.
19. Gunthard HF, Wong JK, Spina CA et al. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis 2000; 181: 522-531.